Skip to content

Epoetin beta

Procrit, NeoRecormon (epoetin beta) is a protein pharmaceutical. Epoetin beta was first approved as Procrit on 1997-07-16. It has been approved in Europe to treat anemia, autologous blood transfusion, chronic kidney failure, and neoplasms.
Trade Name NeoRecormon
Common Name Epoetin beta
Indication anemia, autologous blood transfusion, chronic kidney failure, neoplasms
Drug Class Erythropoietins
Epoetin beta
Get full access now